{
    "ticker": "MTCR",
    "name": "MediWound Ltd.",
    "description": "MediWound Ltd. is a biopharmaceutical company specializing in innovative therapies for the treatment of severe wounds and burns. Founded in 2001 and headquartered in Yavne, Israel, the company is dedicated to developing and commercializing novel therapies that address unmet medical needs in the wound care market. MediWound's lead product, NexoBrid, is a biologically derived topical gel that selectively removes eschar from burn wounds, facilitating a more effective and less painful treatment process compared to traditional methods. The product has received regulatory approvals in various regions, including Europe and Israel, and is currently being evaluated in clinical trials for additional indications. MediWound also focuses on developing other advanced wound care products and has a robust pipeline aimed at improving patient outcomes and reducing healthcare costs. The company's mission is to enhance the quality of life for patients suffering from severe wounds and to become a global leader in the wound care industry through innovation and excellence in clinical development and commercialization.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Yavne, Israel",
    "founded": "2001",
    "website": "https://www.mediwound.com",
    "ceo": "Gal Cohen",
    "social_media": {
        "twitter": "https://twitter.com/MediWound",
        "linkedin": "https://www.linkedin.com/company/medi-wound-ltd"
    },
    "investor_relations": "https://www.mediwound.com/investors",
    "key_executives": [
        {
            "name": "Gal Cohen",
            "position": "CEO"
        },
        {
            "name": "Rami Eliahu",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Wound Care Products",
            "products": [
                "NexoBrid",
                "Eschar Removal Solutions"
            ]
        }
    ],
    "seo": {
        "meta_title": "MediWound Ltd. | Innovative Wound Care Solutions",
        "meta_description": "Learn about MediWound Ltd., a leader in innovative therapies for wound care. Explore their products, clinical trials, and commitment to improving patient outcomes.",
        "keywords": [
            "MediWound",
            "Wound Care",
            "Biopharmaceuticals",
            "NexoBrid",
            "Burn Treatment",
            "Biologics"
        ]
    },
    "faq": [
        {
            "question": "What does MediWound specialize in?",
            "answer": "MediWound specializes in innovative therapies for severe wounds and burns."
        },
        {
            "question": "What is NexoBrid?",
            "answer": "NexoBrid is a topical gel that selectively removes eschar from burn wounds."
        },
        {
            "question": "Where is MediWound headquartered?",
            "answer": "MediWound is headquartered in Yavne, Israel."
        },
        {
            "question": "When was MediWound founded?",
            "answer": "MediWound was founded in 2001."
        }
    ],
    "competitors": [
        "AMRN",
        "NVCR",
        "MGTI"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "ABBV"
    ]
}